Schreiner MediPharm, a Germany-based global provider of functional label solutions for the pharmaceutical industry, has developed an Autoinjector-Label with special protection against abrasion for the allergy emergency drug epinephrine from Teva. Allowing vital user and product information to remain legible over an extended period of time, the label won an award in the 2019 TLMI Competition. 
 
The label developed by Schreiner MediPharm for Teva’s adrenaline injector is provided with abrasion- and scratch-resistant reverse printing. As a result, it is particularly resistant against chemical and mechanical impacts it may encounter while being carried, for example, in a purse or backpack. 
 
Due to its special material construction and design adapted to the autoinjector’s shape, the marking label securely adheres to the device. Thus, the vital product and user information is reliably legible and readily available at all times. An additional cover protecting the label against abrasion or separation is not necessary, which reduces waste and environmental footprint. For product and patient safety, the label features a perforation that clearly and irreversibly indicates any first opening of the cap and thus any potential tampering attempt.